The effect of growth hormone replacement therapy on the morphological and functional changes in the left ventricle in patients with adult-onset growth hormone deficiency.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this clinical trial publication.

The aim of the study was to evaluate the effect of growth hormone (GH) replacement therapy on the morphological and functional changes in the left ventricle (LV) in patients with GH deficiency (GHD).

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

Patients with adult-onset GHD were treated with GH.

Transthoracic echocardiography was performed at baseline and after 6 and 12 months of the treatment.

How the Study Was Run

Interventricular septal thickness (IVST), posterior wall thickness (PWT), left ventricular end-diastolic diameter (LVEDD), left ventricular end-diastolic volume (LVEDV), left ventricular mass (LVM), stroke volume (SV) and left ventricular ejection fraction (LVEF) were evaluated at echocardiography, and the values at respective time points were compared by a paired t-test.

In addition, a gender-stratified analysis was performed.

What Was Measured

PubMed files the paper under topics including Echocardiography, Heart Ventricles, Hormone Replacement Therapy, Human Growth Hormone, Hypopituitarism, Sex Characteristics and Stroke Volume.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2014 (Wiener klinische Wochenschrift), a journal based in Austria.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.